Open AccessClinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial
Author(s) -
Suparna Chatterjee,
Tuhin Kanti Biswas,
Arup Dutta,
Gairik Sengupta,
Anupam Mitra,
Soumi Kundu
Publication year - 2011
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.75667
Subject(s) - cefpodoxime , exacerbation , medicine , chronic bronchitis , gemifloxacin , bronchitis , tolerability , randomized controlled trial , adverse effect , clinical trial , antibacterial agent , antibiotics , microbiology and biotechnology , biology
Acute exacerbation of chronic bronchitis (AECB) is a commonly encountered problem and those suspected to be due to bacterial infections require antibiotic therapy. This randomized, controlled trial was designed to evaluate the effectiveness and safety of gemifloxacin, a new fluoroquinolone, versus cefpodoxime, an oral third-generation cephalosporin, for the treatment of mild to moderately severe cases of AECB.